441 related articles for article (PubMed ID: 8594425)
1. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
[TBL] [Abstract][Full Text] [Related]
2. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
[TBL] [Abstract][Full Text] [Related]
3. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
[TBL] [Abstract][Full Text] [Related]
4. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
[TBL] [Abstract][Full Text] [Related]
5. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
[TBL] [Abstract][Full Text] [Related]
7. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
Labas P; Ohrádka B; Vladimír J; Cambal M
Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
[TBL] [Abstract][Full Text] [Related]
10. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
[TBL] [Abstract][Full Text] [Related]
11. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
13. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
15. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
16. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
[TBL] [Abstract][Full Text] [Related]
19. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
